newsfilter
← Latest News
PR Newswire·

Allergan Aesthetics Reports Improved Satisfaction With Facial Appearance Following Aesthetic Treatment in Two Studies of Patients on GLP-1 Medications

ABBV
  • Allergan Aesthetics presented results from two Phase 4 studies, HARMONY IN DIVERSITY and HALO, at the ASDS 2026 Annual Meeting regarding aesthetic treatments for adults on GLP-1 medications.
  • HARMONY IN DIVERSITY is the first study to evaluate a combined regimen of neurotoxin, hyaluronic acid (HA) injectables, and skincare in this population.
  • In the HARMONY IN DIVERSITY medical weight loss cohort of 30 adults, participants reported a statistically significant 42.4-point improvement in facial appearance satisfaction and improvements in skin quality, psychological function, and social function.
  • Interim results from the HALO study of 25 adults treated with HA injectables showed 95.7% of participants were satisfied or very satisfied that they still looked like themselves.
  • HALO interim data also indicated a 39.6-point mean improvement in facial appearance satisfaction, with 82.6% satisfied with a natural look and 88% satisfied with natural skin appearance.
  • Additional findings from HARMONY IN DIVERSITY Cohort 1 included a 42.0-point mean improvement in facial appearance satisfaction for 100 participants across diverse skin types following multimodal face and neck treatment.
  • An exploratory digital image analysis showed similar outcomes for glabellar line severity and brow position between investigational trenibotulinumtoxinE and BOTOX Cosmetic (onabotulinumtoxinA).
  • Four clinical studies evaluated a topical serum containing exosomes derived from human fibroblasts, showing significant improvements in skin tone evenness, smoothness, and lower facial sagging.
  • A separate presentation examined sequencing strategies for combining cryolipolysis and electromagnetic muscle stimulation for abdominal body contouring.
  • Most treatment-related adverse events reported in the studies were mild, nonserious, and resolved without intervention, with no evidence of distant toxin spread.
  • Safety information reiterated boxed warnings for BOTOX Cosmetic regarding the distant spread of toxin effects, including potential swallowing and breathing difficulties.
  • Important safety information for JUVÉDERM fillers highlighted risks of intravascular injection leading to vision impairment, stroke, or skin necrosis, along with contraindications for severe allergies.
Company
AbbVie
Keywords
AbbVie